1. Madsen, Daniel H, Szabo, Roman, Molinolo, Alfredo A, Bugge, Thomas H. . TMPRSS13 deficiency impairs stratum corneum formation and epidermal barrier acquisition. In The Biochemical journal, 461, 487-95. doi:10.1042/BJ20140337. https://pubmed.ncbi.nlm.nih.gov/24832573/
2. Gatineau, Jérôme, Nidercorne, Charlotte, Dupont, Aurélie, Niedergang, Florence, Castellano, Flavia. 2022. IL4I1 binds to TMPRSS13 and competes with SARS-CoV-2 spike. In Frontiers in immunology, 13, 982839. doi:10.3389/fimmu.2022.982839. https://pubmed.ncbi.nlm.nih.gov/36131918/
3. Kido, Hiroshi, Okumura, Yuushi. 2008. MSPL/TMPRSS13. In Frontiers in bioscience : a journal and virtual library, 13, 754-8. doi:. https://pubmed.ncbi.nlm.nih.gov/17981585/
4. Varela, Fausto A, Foust, Victoria L, Hyland, Thomas E, Todi, Sokol V, List, Karin. 2020. TMPRSS13 promotes cell survival, invasion, and resistance to drug-induced apoptosis in colorectal cancer. In Scientific reports, 10, 13896. doi:10.1038/s41598-020-70636-4. https://pubmed.ncbi.nlm.nih.gov/32807808/
5. Murray, Andrew S, Hyland, Thomas E, Sala-Hamrick, Kimberley E, Varela, Fausto A, List, Karin. 2020. The cell-surface anchored serine protease TMPRSS13 promotes breast cancer progression and resistance to chemotherapy. In Oncogene, 39, 6421-6436. doi:10.1038/s41388-020-01436-3. https://pubmed.ncbi.nlm.nih.gov/32868877/
6. Hashimoto, Tomio, Kato, Minoru, Shimomura, Takeshi, Kitamura, Naomi. 2010. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor. In The FEBS journal, 277, 4888-900. doi:10.1111/j.1742-4658.2010.07894.x. https://pubmed.ncbi.nlm.nih.gov/20977675/
智鼠故事 
